mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

doi:10.1126/science.abg9175

GSTDTAP > 气候变化

DOI	10.1126/science.abg9175
	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
	Leonidas Stamatatos; Julie Czartoski; Yu-Hsin Wan; Leah J. Homad; Vanessa Rubin; Hayley Glantz; Moni Neradilek; Emilie Seydoux; Madeleine F. Jennewein; Anna J. MacCamy; Junli Feng; Gregory Mize; Stephen C. De Rosa; Andrés Finzi; Maria P. Lemos; Kristen W. Cohen; Zoe Moodie; M. Juliana McElrath; Andrew T. McGuire
	2021-06-25
发表期刊	Science
出版年	2021
英文摘要	Postinfection immune protection against severe acute respiratory syndrome coronavirus 2 reinfection is not fully understood. It will be devastating if waves of new variants emerge that undermine natural immune protection. Stamatatos et al. investigated immune responsiveness 4 to 8 months after previously infected individuals were given a messenger RNA–based vaccine developed for the original Wuhan variant (see the Perspective by Crotty). Before vaccination, postinfection serum antibody neutralization responses to virus variants were variable and weak. Vaccination elevated postinfection serum-neutralizing capacity approximately 1000-fold against Wuhan-Hu-1 and other strains, and serum neutralization against the variant B.1.351 was enhanced. Although responses were relatively muted against the variant, they still showed characteristic memory responses. Vaccination with the Wuhan-Hu-1 variant may thus offer a valuable boost to protective responses against subsequent infection with variant viruses. Science , abg9175, this issue p. [1413][1]; see also abj2258, p. [1392][2] Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have raised concerns about resistance to neutralizing antibodies elicited by previous infection or vaccination. We examined whether sera from recovered and naïve donors, collected before and after immunizations with existing messenger RNA (mRNA) vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants. Prevaccination sera from recovered donors neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351, but a single immunization boosted neutralizing titers against all variants and SARS-CoV-1 by up to 1000-fold. Neutralization was a result of antibodies targeting the receptor binding domain and was not boosted by a second immunization. Immunization of naïve donors also elicited cross-neutralizing responses but at lower titers. Our study highlights the importance of vaccinating both uninfected and previously infected persons to elicit cross-variant neutralizing antibodies. [1]: /lookup/doi/10.1126/science.abg9175 [2]: /lookup/doi/10.1126/science.abj2258
领域	气候变化 ; 资源环境
URL	查看原文
引用统计
文献类型	期刊论文
条目标识符	http://119.78.100.173/C666/handle/2XK7JSWQ/334139
专题	气候变化资源环境科学
推荐引用方式 GB/T 7714	Leonidas Stamatatos,Julie Czartoski,Yu-Hsin Wan,et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection[J]. Science,2021.
APA	Leonidas Stamatatos.,Julie Czartoski.,Yu-Hsin Wan.,Leah J. Homad.,Vanessa Rubin.,...&Andrew T. McGuire.(2021).mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.Science.
MLA	Leonidas Stamatatos,et al."mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection".Science (2021).